Bioventus (BVS) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
1 Dec, 2025Executive summary
Annual Meeting of Stockholders scheduled for June 11, 2024, with this supplement updating the original proxy statement dated April 26, 2024.
All prior information in the proxy statement remains unchanged except as specifically supplemented.
Voting matters and shareholder proposals
Stockholders are encouraged to review proposals and may contact the proxy solicitor for assistance with voting.
Board of directors and corporate governance
Morrow Sodali LLC has been retained to assist with proxy solicitation for the annual meeting.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Bioventus
- Q4 2025 saw double-digit organic growth, margin expansion, and record cash flow.BVS
Q4 20255 Mar 2026 - Q2 revenue up 10.3%, guidance raised, with $31.9M impairment and litigation settlement.BVSQ2 20242 Feb 2026
- Accelerated growth, margin expansion, and debt reduction position for substantial value creation.BVSCanaccord Genuity 44th Annual Growth Conference & Private Company Showcase 20242 Feb 2026
- Q3 revenue up 15%, guidance raised, divestiture and litigation drive key financial changes.BVSQ3 202416 Jan 2026
- Transformation and strategic investments drive strong growth, high margins, and global expansion.BVS44th Annual J.P. Morgan Healthcare Conference14 Jan 2026
- Strong 2024 growth and margin gains set up for doubled free cash flow and lower leverage in 2025.BVS43rd Annual J.P. Morgan Healthcare Conference 202510 Jan 2026
- Q4 revenue up 14%, margin expansion, and 2025 guidance targets 6–8% organic growth.BVSQ4 202426 Dec 2025
- Shelf registration enables $200M in offerings and large shareholder sales, with dilution risk.BVSRegistration Filing16 Dec 2025
- Strong growth, margin expansion, and innovation drive future investment flexibility and value.BVSPiper Sandler 37th Annual Healthcare Conference3 Dec 2025